Skip to main content
. Author manuscript; available in PMC: 2013 May 6.
Published in final edited form as: Am J Transplant. 2011 Nov 4;12(2):379–387. doi: 10.1111/j.1600-6143.2011.03826.x

Figure 1. Cumulative incidence plots of allograft loss (A) and all-cause mortality (B) in the overall population, and all-cause mortality among those without a history of malignancy (C) according to baseline use versus non-use of mTOR inhibitors.

Figure 1

The mortality plots considered allograft loss as a competing risk, and the allograft loss considered death as a competing risk. Study participants who remained event-free were censored at the end of the 3-year observation period. No participants were prematurely lost to follow-up.